RET, ROS1 and ALK fusions in lung cancer
暂无分享,去创建一个
Yuki Togashi | Young Lim Choi | Kengo Takeuchi | Hiroyuki Mano | Hirofumi Uehara | Ken Nakagawa | Y. Ishikawa | M. Soda | H. Mano | R. Suzuki | H. Uehara | H. Ninomiya | S. Okumura | K. Takeuchi | Manabu Soda | Ritsuro Suzuki | Seiji Sakata | Satoko Hatano | Reimi Asaka | Wakako Hamanaka | Hironori Ninomiya | Yukitoshi Satoh | Sakae Okumura | Yuichi Ishikawa | Y. Satoh | K. Nakagawa | Yuki Togashi | S. Hatano | W. Hamanaka | Y. L. Choi | S. Sakata | R. Asaka
[1] Yuki Togashi,et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. , 2008, Cancer research.
[2] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[3] K. Arihiro,et al. RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose. , 2008, Cancer research.
[4] A. Bounacer,et al. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation , 1997, Oncogene.
[5] P. Sorensen,et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. , 2002, Cancer cell.
[6] M. Santoro,et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas , 1990, Cell.
[7] Yuki Togashi,et al. EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[8] Laura A. Sullivan,et al. Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.
[9] Y. Ishikawa,et al. Pulmonary Inflammatory Myofibroblastic Tumor Expressing a Novel Fusion, PPFIBP1–ALK: Reappraisal of Anti-ALK Immunohistochemistry as a Tool for Novel ALK Fusion Identification , 2011, Clinical Cancer Research.
[10] Y. Ishikawa,et al. Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts , 2008, Clinical Cancer Research.
[11] S. Dhanasekaran,et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. , 2008, Cancer research.
[12] Y. Ishikawa,et al. Identification of anaplastic lymphoma kinase fusions in renal cancer , 2012, Cancer.
[13] Y. Ishikawa,et al. KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer , 2009, Clinical Cancer Research.
[14] M. Soda,et al. Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma , 2011, Haematologica.
[15] Takayuki Kosaka,et al. Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.
[16] Takashi lto,et al. Activated RET oncogene in thyroid cancers of children from areas contaminated by Chernobyl accident , 1994, The Lancet.
[17] J. Ritz,et al. Activation of a novel human transforming gene, ret, by DNA rearrangement , 1985, Cell.
[18] Takashi Yamasaki,et al. Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma , 2010, Journal of Clinical Pathology.